Business
Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
Bioeq AG ("Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited ("Zydus"), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizuma
About this update from Zydus Lifesciences Limited
[{"type":"text","content":"NUFYMCO® BLA has been approved by the USFDA","length":43,"tagName":"p","attribs":{}},{"type":"text","content":"AHMEDABAD, India and ZUG, Switzerland, Dec. 23, 2025 /PRNewswire/ -- Bioeq AG ("Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited ("Zydus"), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO® has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025. This transaction marks an expansion of Zydus' U.S. biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda®2 (Pembrolizumab).","length":924,"tagName":"p"},{"type":"image","alt":"Zydus Lifesciences Limited Logo","displaySize":"","headline":null,"caption":"Zydus Lifesciences Limited Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":231,"url":"https://media.zenfs.com/en/prnewswire.com/9adf39666b3ed654ea074c9c9de63625"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f5DyqCrheK2N94pbyhJnjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQwNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9adf39666b3ed654ea074c9c9de63625","width":400,"height":231}}},{"type":"text","content":"Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO® in the U.S. market.","length":235,"tagName":"p"},{"type":"text","content":"Speaking on the development, Managing Director of Zydus Lifesciences Limited, Dr. Sharvil P. Patel, said, "We are happy to collaborate with Bioeq to bring an interchangeable biosimilar to Lucentis® (Ranibizumab) in the US market. Through this partnership, we will leverage our combined expertise and resources to accelerate organisational growth while ensuring maximum value to patients through an expanded access to affordable ophthalmology care.&...